Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here


Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

Afrezza Promotional Update; MannKind Receives $4.9M Forgivable Loan

Here is a brief preview of this blast: MannKind recently updated the Afrezza patient website with new promotional messaging, which aligns with the recent corporate rebranding. Additionally, MannKind announced the company has received a forgivable loan under the Paycheck Protection Program of the CARES Act. Below, FENIX provides an analysis of the updated Afrezza messaging as well as brief thoughts on the impact of COVID-19 to MannKind and the Afrezza brand.

About The Author

Matthew Maryniak

President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.